Heart Failure: Genotypes and Phenotypes

Description

Leaning Objectives
Upon completion of this activity, you should be able to: 

Evaluate the epidemiology, risk factors, comorbidities, and community aspects associated with HF to determine best practices for care.
Distinguish pathophysiologic characteristics of current classifications of phenotypes when diagnosing HF to analyze best HF risk stratification, prevention, and management strategies.

Faculty

Melvin Echols, MD, MSCR, FACC (Chair) 

Morehouse School of Medicine

Atlanta, Georgia

Disclosures

Consultant Fees/Honoraria: Abbott Laboratories, Bayer Healthcare Pharmaceuticals, National Academy for Continuing Education, Novartis Corporation

Target Audience  
The primary target audience for this education are members of the HF Care Team, including physicians, advanced practice providers (APPs), PharmDs, and other HCPs.

Important Dates 
Date of Release: April 30, 2026
Term of Approval/Date of Expiration: April 30, 2027

Acknowledgement
This activity is supported by an unrestricted educational grant from Bayer AG.

Summary

Availability:

On-Demand

Access expires on Apr 30, 2027

Cost:

FREE

Credit Offered:

No Credit Offered